Business Context and Reporting Period
This Form 6-K filing by Mereo Biopharma Group Plc, a clinical-stage UK-based biopharmaceutical company focused on rare diseases, covers the month of April 2019. The report, dated April 26, 2019, serves as a notification of director dealing in compliance with the EU Market Abuse Regulation.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory notification regarding a specific equity transaction involving a non-executive director.
Material Changes
On April 23, 2019, Deepa Pakianathan, a non-executive director, received 256,734 American Depositary Shares (ADSs). This issuance was in consideration for the acquisition of stock in OncoMed Pharmaceuticals, Inc. The transaction involved an exchange rate of 0.127694 Stock Units in OncoMed Pharmaceuticals, Inc. per ADS, resulting in an aggregated volume of 2,010,542 stock units in OncoMed Pharmaceuticals, Inc.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The transaction was conducted outside a trading venue.
Key Facts for Investor Verification
- Transaction Date: April 23, 2019.
- Recipient: Deepa Pakianathan (Non-Executive Director).
- Instrument: 256,734 Mereo BioPharma Group plc ADSs.
- Consideration: Acquisition of stock in OncoMed Pharmaceuticals, Inc.
- Exchange Rate: 0.127694 OncoMed Stock Units per ADS.
- Regulatory Basis: EU Market Abuse Regulation notification.